Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AVI-7537
- Development stage
- Discontinued
- Lead developer
- Sarepta Therapeutics
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
AVI-7537 is an antisense phosphorodiamidate morpholino oligomer (PMOplus) designed to inhibit Ebola virus replication. It specifically targets the mRNA of the Ebola virus VP24 gene, blocking its translation and thereby preventing viral replication. Developed as a single agent after initial combination studies, AVI-7537 was investigated for use against Ebola virus disease and advanced into clinical trials, including Phase 1 studies in healthy volunteers. The drug was developed by Sarepta Therapeutics and represents a targeted antiviral approach using antisense oligonucleotide technology.
02
Targets
vRNA (Coronavirus viral RNA)VP24 (Ebola virus VP24)
Beyond the preview
Go deeper on AVI-7537.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AVI-7537.